Literature DB >> 22228177

Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing.

Tibor Kempf1, Alexander Zarbock, Dietmar Vestweber, Kai C Wollert.   

Abstract

The wound healing response after myocardial infarction (MI) involves a cascade of molecular and cellular events that lead to a replacement of the necrotic area with a collagen-rich scar. Clearance of necrotic debris by neutrophils, monocytes, and macrophages is a critical component of infarct healing; however, tight control and timely repression of this inflammatory response is important to prevent excessive tissue degradation leading to infarct expansion and heart failure. Genetic ablation or blockade of anti-inflammatory pathways tends to be detrimental after MI, whereas genetic ablation of pro-inflammatory pathways tends to be beneficial. Accordingly, therapies enhancing endogenous anti-inflammatory pathways or blocking endogenous pro-inflammatory pathways have been found to improve wound healing and to reduce the risk of heart failure in rodent models of acute MI. Besides their scavenger function, inflammatory cells promote healing by stimulating angiogenesis and granulation tissue formation via paracrine factors. Moreover, signaling mediators that are active in inflammatory cells may be active also in non-inflammatory cell types involved in infarct healing. Some anti-inflammatory interventions are therefore deleterious. However, interventions that carefully adjust the balance between the essential and detrimental facets of inflammation may provide new therapeutic opportunities for patients with large MIs who continue to be at risk of developing heart failure, despite modern reperfusion and anti-remodeling strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228177     DOI: 10.1007/s00109-011-0847-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  68 in total

1.  Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury.

Authors:  Caterina Curato; Svetlana Slavic; Jun Dong; Anna Skorska; Wassim Altarche-Xifró; Kapka Miteva; Elena Kaschina; Andreas Thiel; Hans Imboden; Jianan Wang; Ulrike Steckelings; Gustav Steinhoff; Thomas Unger; Jun Li
Journal:  J Immunol       Date:  2010-10-08       Impact factor: 5.422

Review 2.  Taming the PI3K team to hold inflammation and cancer at bay.

Authors:  Emilio Hirsch; Elisa Ciraolo; Alessandra Ghigo; Carlotta Costa
Journal:  Pharmacol Ther       Date:  2008-03-05       Impact factor: 12.310

Review 3.  Innate immune signaling in cardiac ischemia.

Authors:  Fatih Arslan; Dominique P de Kleijn; Gerard Pasterkamp
Journal:  Nat Rev Cardiol       Date:  2011-03-29       Impact factor: 32.419

4.  Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice.

Authors:  Prasanna Krishnamurthy; Erin Lambers; Suresh Verma; Tina Thorne; Gangjian Qin; Douglas W Losordo; Raj Kishore
Journal:  FASEB J       Date:  2010-03-10       Impact factor: 5.191

Review 5.  Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease.

Authors:  Ruenn Chai Lai; Tian Sheng Chen; Sai Kiang Lim
Journal:  Regen Med       Date:  2011-07       Impact factor: 3.806

Review 6.  Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications.

Authors:  Han W Kim; Afshin Farzaneh-Far; Raymond J Kim
Journal:  J Am Coll Cardiol       Date:  2009-12-29       Impact factor: 24.094

7.  Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.

Authors:  Mauro Siragusa; Rajesh Katare; Marco Meloni; Federico Damilano; Emilio Hirsch; Costanza Emanueli; Paolo Madeddu
Journal:  Circ Res       Date:  2010-01-07       Impact factor: 17.367

8.  CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells.

Authors:  Marcin Dobaczewski; Ying Xia; Marcin Bujak; Carlos Gonzalez-Quesada; Nikolaos G Frangogiannis
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

9.  Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction.

Authors:  Susanne W M van den Borne; Jack P M Cleutjens; Roeland Hanemaaijer; Esther E Creemers; Jos F M Smits; Mat J A P Daemen; W Matthijs Blankesteijn
Journal:  Cardiovasc Pathol       Date:  2008-03-04       Impact factor: 2.185

Review 10.  Large animal models of heart failure: a critical link in the translation of basic science to clinical practice.

Authors:  Jennifer A Dixon; Francis G Spinale
Journal:  Circ Heart Fail       Date:  2009-05       Impact factor: 8.790

View more
  24 in total

Review 1.  Image-guided therapies for myocardial repair: concepts and practical implementation.

Authors:  Frank M Bengel; Richard T George; Karl H Schuleri; Albert C Lardo; Kai C Wollert
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2013-05-29       Impact factor: 6.875

2.  [Effect of dexmedetomidine postconditioning on myocardial ischemia-reperfusion injury and inflammatory response in diabetic rats].

Authors:  Jing Hu; Xiao-Yu Gu; Yan Meng; Ya Wang; Qin Gao; Zheng-Hong Li; Xiao-Hong Li; Xiang-Yang Cheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-11-20

3.  Myocardial healing requires Reg3β-dependent accumulation of macrophages in the ischemic heart.

Authors:  Holger Lörchner; Jochen Pöling; Praveen Gajawada; Yunlong Hou; Viktoria Polyakova; Sawa Kostin; Juan M Adrian-Segarra; Thomas Boettger; Astrid Wietelmann; Henning Warnecke; Manfred Richter; Thomas Kubin; Thomas Braun
Journal:  Nat Med       Date:  2015-03-09       Impact factor: 53.440

4.  Targeting post-infarct inflammation by PET imaging: comparison of (68)Ga-citrate and (68)Ga-DOTATATE with (18)F-FDG in a mouse model.

Authors:  James T Thackeray; Jens P Bankstahl; Yong Wang; Mortimer Korf-Klingebiel; Almut Walte; Alexander Wittneben; Kai C Wollert; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-12       Impact factor: 9.236

5.  Stanniocalcin-1 attenuates ischemic cardiac injury and response of differentiating monocytes/macrophages to inflammatory stimuli.

Authors:  Arezoo Mohammadipoor; Ryang Hwa Lee; Darwin J Prockop; Thomas J Bartosh
Journal:  Transl Res       Date:  2016-07-09       Impact factor: 7.012

Review 6.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

7.  Cyclovirobuxinum D suppresses lipopolysaccharide-induced inflammatory responses in murine macrophages in vitro by blocking JAK-STAT signaling pathway.

Authors:  Dan Guo; Jing-Rong Li; Ying Wang; Lin-Sheng Lei; Chuan-Lin Yu; Na-Na Chen
Journal:  Acta Pharmacol Sin       Date:  2014-04-21       Impact factor: 6.150

8.  Knockdown of TNF-α by DNAzyme gold nanoparticles as an anti-inflammatory therapy for myocardial infarction.

Authors:  Inthirai Somasuntharam; Kevin Yehl; Sheridan L Carroll; Joshua T Maxwell; Mario D Martinez; Pao-Lin Che; Milton E Brown; Khalid Salaita; Michael E Davis
Journal:  Biomaterials       Date:  2015-12-21       Impact factor: 12.479

Review 9.  Mechanisms and consequences of inflammatory signaling in the myocardium.

Authors:  Jihyun Ahn; Jaetaek Kim
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

10.  Emerging imaging targets for infiltrative cardiomyopathy: Inflammation and fibrosis.

Authors:  Frank M Bengel; Tobias L Ross
Journal:  J Nucl Cardiol       Date:  2018-07-02       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.